(Bloomberg) -- Eli Lilly & Co. may attract more
lawsuits alleging it failed to warn users that a psychiatric drug
was linked to diabetes after the pharmaceutical company received
a letter from U.S. regulators.
The U.S. Food and Drug Administration told Lilly in March it
would delay the approval of Symbyax for depression because the
agency wanted more information about the risk of diabetes in the
medicine's prescribing label. Symbyax combines Lilly's
antipsychotic pill Zyprexa and the antidepressant Prozac.
Read more at Bloomberg Exclusive News
lawsuits alleging it failed to warn users that a psychiatric drug
was linked to diabetes after the pharmaceutical company received
a letter from U.S. regulators.
The U.S. Food and Drug Administration told Lilly in March it
would delay the approval of Symbyax for depression because the
agency wanted more information about the risk of diabetes in the
medicine's prescribing label. Symbyax combines Lilly's
antipsychotic pill Zyprexa and the antidepressant Prozac.
Read more at Bloomberg Exclusive News
No comments:
Post a Comment